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Summary By measuring peripheral drug levels in plasma, the effect of combining albumin microspheres with
angiotensin II on systemic exposure to 5FU when administered by bolus injection into the hepatic artery in
patients with advanced colorectal liver metastases has been assessed. The results suggest that despite hepatic
arterial administration of 5FU, there was no reduction in systemic exposure when compared with that
associated with intravenous injection of the same dose. Neither albumin microspheres nor angiotensin II
appeared to improve the regional advantage. There have been a number of reports relating the plasma levels
of cytotoxic agents with pharmacodynamic parameters. We have shown significant direct correlations between
5FU clearance and 1 week post treatment platelet and white cell counts, and an inverse relationship between
the area under the 5FU plasma concentration-time curve (AUC) and 1 week post treatment platelet count
and white cell count respectively.
The failure and toxicity of systemic chemotherapy in the
treatment of liver metastases of colorectal origin has led to
increasing interest in locoregional therapy (Taylor, 1985).
Most antineoplastic agents have steep dose response curves
and systemic toxicity can often be related to some aspect of
the drug's plasma concentration-time profile (Powis, 1986).
The hypothesis underlying rational use of intraarterial
chemotherapy is that it should allow the generation of high
drug concentrations at the tumour with reduced systemic
exposure and hence toxicity (Dedrick et al., 1978). Attempts
have been made to increase tumour drug delivery and hence
therapeutic index by altering the organ blood flow during
cytotoxic drug infusion. Sasaki et al. (1985) have shown that
infusion of the vasoconstrictor angiotensin II via the hepatic
artery increases tumour blood-flow by 50%, relative to the
surrounding normal tissue. Ensminger et al. (1985) adopted a
different approach and demonstrated that the administration
of biodegradable starch microspheres (40,jm diam.) via the
hepatic artery, increases the hepatic uptake of mitomycin C,
and reduces the concentration of drug in the systemic
circulation. Our aim in the present study was to examine the
pharmacokinetic and pharmacodynamic advantages of the
sequential administration of 5FU with albumin microspheres
during angiotensin II infusion via the hepatic artery, in
patients with advanced hepatic metastases from colorectal
cancer.
Materials and methods
Nine patients with advanced hepatic metastases from a
colorectal primary tumour were included in the study. Esti-
mations of the percentage replacement of liver parenchyma
by tumour, were based on Tc99m tin colloid scans performed
prior to the study.
All patients underwent insertion of a 'Portacath' arterial
silicone catheter and subcutaneous reservoir (I.D. 0.76mm,
O.D. 2.29mm, system 320, Pharmacia, Pharmacia House,
Midsummer Boulevard, Milton Keynes, UK). At laparotomy,
the stomach and duodenum were mobilised and the lesser
sac opened to identify the gastroduodenal artery at the
junction with the hepatic artery. These vessels were
mobilised, and a standard cholecystectomy performed to
obviate gallbladder ischaemia. The catheter was then placed
in a tunnel made between a subcutaneous pocket created on
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the right chest wall and the peritoneal cavity. The reservoir
was then sutured into position over a rib within the
subcutaneous pocket. The gastroduodenal artery was ligated
distally and cannulated so that the catheter tip lay at the
junction of the gastroduodenal and hepatic arteries. The
catheter and reservoir were then filled with heparinised
saline, which was replaced by flushing daily in the immediate
post-operative period, and then once weekly.
Albumin microspheres were prepared by a technique
involving stabilisation with glutaraldehyde of a water in oil
emulsion containing protein (Lee et al., 1981). The basic
system has been modified by us to produce microspheres of
a size suitable for entrapment in terminal capillaries.
(Willmott et al., 1985). Human serum albumin (600mg) was
dissolved in 1 mM phosphate buffer containing 0.1% SDS
(1 ml) and diluted with water (1.8ml). The albumin solution
is emulsified in an oil phase of cotton seed oil and petroleum
ether, and the protein cross-linked with 25% gluteraldehyde
(150jil) to stabilise the microspheres. Following consecutive
washes in petroleum ether/isopropanol/PBS/0.5% tween, and
PBS/0.2% tween to remove particles <7,um in diameter, the
microspheres were ready for use. All procedures were carried
out in a sterile products unit which maintains a sterile
environment to the required British standard. This ensured
that the microspheres were sterile, and an aliquot from each
dose was formally checked by solubilisation with trypsin
prior to sterility testing. The size of the microspheres was
measured by Coulter counter or laser diffraction (Malvern
Instruments, Malvern, UK) and was found to be 20-40,jm
in diameter (50% weight average). Between 60 and 90
million particles constitute a bolus dose as used in the
pharmacokinetic studies described in this paper.
In a preliminary phase I study to determine the maximum
tolerated dose of albumin microspheres, angiotensin II (Ciba
Laboratories) was infused at a rate of 10pgmin-1 for 4min
into the hepatic artery. This caused an increase in systolic
blood-pressure of between 25 and 40mmHg but resulted in
no ill effects. A bolus injection of albumin microspheres was
given at t = 100 sec by the same route followed by a 1 g bolus
of 5FU.
Microsphere doses were escalated from 100 to 300mg in
50mg increments. Pharmacokinetic- studies were performed
for each of the four treatments listed below. They were per-
formed at weekly intervals and in random order. For each
study, the preparations were administered as immediately
consecutive boluses unless otherwise stated.
1. i.v. 5FU: Intravenous injection of 1 g 5FU.
2. i.a. 5FU: Hepatic intraarterial injection of 1 g 5FU.
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3. i.a. AMS; 5FU: Hepatic intraarterial injection of 300mg
albumin microspheres (AMS), followed by hepatic
intraarterial injection of 1 g 5FU.
4. i.a. All; AMS; 5FU: Hepatic intraarterial infusion of
angiotensin II at a rate of 0pgmin-I for 4min (All);
at t = 100 sec, an hepatic intraarterial injection of AMS,
followed by an intrahepatic arterial injection of I g 5FU.
Blood samples (10ml) were withdrawn from a canula in
an antecubital vein and collected into lithium heparin tubes
before 5-fluorouracil administration, and at intervals
thereafter (5, 30, 60, 90, 120, 180 and 240min). The blood
samples were centrifuged (2000 rpm for 5min) and the
plasma separated and stored at -20°C until analysis. 5FU
plasma concentrations were measured by a sensitive and
specific HPLC method (Christophidis, 1979), with inter- and
intra-assay coefficients of variation of between 5 and 10%.
The 5FU plasma concentration values were fitted to a 2-
compartment open model by non linear least squares fitting
using an in house programme based on the Maquhardt
algorithm (Bevington, 1969). AUC was calculated from time
zero to infinity by the trapezoidal rule.
The white cell and platelet counts were estimated before
and at 1 week after the pharmacokinetic studies. Regression
lines were constructed between AUC, total body clearance of
5FU, 5min serum peak of 5FU, and I week post treatment
white cell and platelet counts, and the percentage change in
white cell and platelet counts following treatment
respectively. Base-line tumour arterio-venous shunting was
assessed in 5 patients by intraarterial injection of 99mTc
labelled albumin microspheres using a glass syringe. The
upper abdomen and thorax were scanned, and both anterior
and posterior views obtained with a gamma camera (IGE
400 A Tomographic gamma camera with low energy parallel
multi-purpose collimator). Regions of interest were drawn
around the liver and lungs, and the relative lung uptake
(RLU) calculated as RLU =Activity (lung-fields)/Activity
(liver+lung-fields).
Results
Tin colloid scans revealed that the patients studied had
extensive replacement of hepatic tissue by tumour (5 patients
> 50% replacement; 4 patients 25-50% parenchymal
replacement). Base-line percent shunting was calculated as
1.41 +0.4% (mean+s.d.), and ranged from 0.4-2.9%.
The maximum dose of albumin microspheres administered
via the hepatic artery was 350 mg. This dose caused
significant right upper quadrant pain in 4 out of 5 patients
studied, so that the recommended dose for clinical trials, and
that used in these pharmacokinetic studies was 300 mg. The
pharmacokinetic results are summarised in Table I.
The plasma 5FU concentrations fitted a 2 compartment
model in most cases, and it was possible to derive drug
clearance and volume of distribution from the model
parameters. It is clear from Table I and Figure 1 that the
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Figure 1 Plasma 5FU concentration - time curves for each
bolus treatment (mean+s.d.), (a) Intravenous injection, 1 g 5FU;
(b) Hepatic arterial injection, 1 g 5FU; (c) Hepatic arterial
injection, AMS; 1 g 5FU; (d) Hepatic arterial injection of All;
AMS; 1 g 5FU.
pharmacokinetics of intraarterial 5FU do not differ
markedly from those following bolus intravenous
administration.
With regard to the pharmacodynamics of 5FU, there were
significant linear correlations between plasma clearance and
Table I Pharmacokinetic studies of intravenous and intrahepatic arterial bolus
injection of 5FU (with and without albumin microspheres and angiotensin II) in
patients with advanced colorectal liver metastases
AUC Clearance 5min t1/2
n mgI min-1 I min- 1 peak mg 11 min
1. i.v. 5FU 9 1172+365 0.94+0.3 39+ 11 17 +5
2. i.a. 5FU. 9 1312+325 0.81+0.2 43+10 17+6
3. i.a. AMS; 5FU 6 1115+481 1.01+0.3 35+ 7 17+6
4. i.a. AII; AMS; 5FU 5 1403 +461 0.78+0.3 39+ 9 17+3
AUC=Area under the plasma 5FU concentration - time curve; t11/2=terminal
disposition phase half-life of 5FU in plasma; All values expressed as mean+s.d.188 J.A. GOLDBERG et al.
1-week post treatment white-cell count (r=0.69; P=0.48)
and platelets (r=0.89; P=0.8). There are significant inverse
linear correlations between AUC for 5FU and 1-week post
treatment white cell and platelet counts (r=0.66, P=0.44;
r=0.88, P=0.77 respectively) (Figure 2).
Of the 9 patients included in the study, 2 died 6.6 and 7.2
months respectively after catheter implantation from disease
progression. The 7 patients still living have been receiving
locoregional 5 fluorouracil therapy for 4.3+2.6 months
(mean+s.d.) at the time of writing. One patient has had
disease progression and was withdrawn from the programme
8.5 months after catheter implantation. The remaining 6
patients currently have stable disease as assessed by
ultrasound and tin colloid scan.
Discussion
In this study, we have attempted to manipulate the
pharmacokinetics of 5FU so as to maximise tumour
exposure and decrease drug delivery to the systemic
compartment. Hepatic 5FU extraction has been measured in
patients with metastatic cancer to the liver and has been
found to be as high as 50% on first pass (Ensminger et al.,
1978). If 50% of 5FU were extracted on first pass following
intraarterial bolus administration as in the present study,
then by using a theoretical model, one could predict that
drug levels reaching the systemic circulation would be one
half of those following intravenous administration of the
same dose. Measures taken to increase tumour drug delivery
by temporarily altering blood flow with vasoactive agents,
and causing a transient reduction in hepatic blood flow by
embolising the hepatic microvascular bed with degradable
albumin microspheres should help to increase hepatic drug
extraction and decrease systemic exposure.
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Figure 2 The correlation between the area under the plasma
5FU concentration - time curve and the platelet count 1 week
after injection of 5FU. (r=0.876; P=0.767).
No differences in the pharmacokinetics of 5FU were seen
when standard systemic was compared with administration
via the hepatic artery. There are a number of possible
explanations for these findings.
Although we have described the kinetics of 5FU using a
linear model, there is evidence to suggest that the drug has
non linear pharmacokinetics after hepaticarterial and
intravenous infusions in cancer patients (Collins et al., 1980;
Wagner et al., 1986).
If there is a saturable mechanism for hepatic extraction of
5FU, then delivery of an intraarterial bolus with generation
of high drug concentrations within the hepatic vascular
compartment could exceed the capacity for tissue uptake and
allow a larger than expected drug dose to reach the systemic
circulation. Reduction of the 5FU infusion rate could
therefore increase the hepatic extraction and reduce systemic
exposure to the cytotoxic agent.
The patients reported in this study had a large hepatic
tumour burden and there is some evidence to suggest that
patients with advanced liver tumours have a reduced hepatic
extraction capacity (Heidelberger, 1975; Mukherjee et al.,
1963). There are supportive animal experimental data for
this hypothesis as rats with liver tumours have been shown
to have an insignificant capacity for metabolic degradation
of pyrimidines (Weber et al., 1971).
A further contributory factor to the apparent loss of
regional advantage through administering 5FU via the
hepatic artery may be the existence of arterio-venous shunts.
However, we found negligible base line shunting in 5
patients studied (Goldberg et al., 1987), so that this would
not account for the similarity of results between intravenous
and intrahepatic arterial 5FU.
Further studies are planned on patients with early meta-
static disease, and we intend to assess the effects of slower
infusion rates of 5FU, and varying the order of microsphere
administration in an attempt to enhance regional selectivity.
The relationship between the pharmacokinetics and
pharmacodynamics of anti-cancer drugs has recently been
reviewed by Powis (1986). There are a number of reports
relating peak plasma levels of 5FU and its AUC, with regard
to 5FU and gastrointestinal toxicity (Au et al., 1982; Byfield
et al., 1983). In the present study significant correlations
between 5FU clearance and 1-week post treatment platelet
and white cell counts, and inverse correlations between AUC
and 1-week post treatment platelet and white cell counts
have been demonstrated. This implies that any attempt to
reduce the systemic 5FU exposure, as manifest by the AUC,
and increase tumour exposure and drug clearance, should
result in decreased myelotoxicity.
The Authors gratefully acknowledge the financial support of the
Cancer Research Campaign and Medical Research Council, thank
Messers A. Setanoiars and M. Bradnam for their expert technical
assistance, and are indebted to Ciba Laboratories for the provision
ofangiotensin II.
References
AU, J.L.S., RUSTUM, Y.M., LEDESMA, E.J., MITTLEMAN, A. &
CREAVEN, P.J. (1982). Clinical pharmacological studies of
concurrent infusion of 5-fluorouracil and thymidine in treatment
of colorectal carcinomas. Cancer Res., 42, 2930.
BEVINGTON, P.R. (1969). Data reduction and error analysis for the
physical sciences. McGraw-Hill: New York, p. 235.
BYFIELD, J.E., FRANKEL, S.S., HORNBECK, C.L., SHARP, T.R. &
FLOYD, R.A. (1983). Relationships between serum 5FU level
(5FU) and toxicity. Proc. Am. Soc. Clin. Oncol., 2, 44.
CHRISTOPHIDIS, N., MIHALY, G. VAJDA, F. & LOUIS, W. (1979).
Comparison of gas and gas-liquid chromatographic assays of 5-
Fluorouracil in plasma. Clin. Chem., 25, 83.
COLLINS, J., DEDRICK, R.L., KING, F.G., SPEYER, J.L. & MYERS,
C.E. (1985). Nonlinear pharmacokinetic models for 5-fluorouracil
in man: Intravenous and intraperitoneal routes. Clin. Pharmacol.
Ther., 28(2), 235.
DEDRICK, R.L., MYERS, C.E., BUNGAY, P.M. & DE VITA, J.R. (1978).
Pharmacokinetic rational for peritoneal drug administration in
the treatment of ovarian cancer. Cancer Treat. Rep., 62, 1.
ENSMINGER, W.D., GYVES, J.W., STEVSON, P. & WALKER-
ANDREWS, S. (1985). Phase I study of hepatic arterial degradable
starch microspheres and mitomycin C. Cancer Res., 45, 4464.LOCO-REGIONAL 5FU IN ADVANCED COLORECTAL LIVER METASTASES 189
ENSMINGER, W.D., ROSOWSKI, A., RASO, V. & 5 others (1978). A
clinical-pharmacological evaluation of hepatic arterial infusions
of 5-Fluoro-2-deoxyuridine and 5-Fluorouracil. Cancer Res., 38,
3784.
GOLDBERG, J.A., BRADNAM, M.S., KERR, D.J. & 5 others (1987).
Arterio-venous shunting of microspheres in patients with
colorectal liver metastases: Errors in assessment due to free
pertechnetate and the effect of Angiotensin II. Nuc. Med. Comm.
(in press).
HEIDELBERGER, C. (1975). Fluorinated pyrimidines and their
nucleotides. In Antineoplastic and immunosuppressive agents. Part
II. Sartorelli and Johns, (eds) p. 193. Springer-Verlag: New
York.
LEE, T.K., SOKOLSKI, J.D. & ROYER, G.P. (1981). Serum albumin
beads: An injectible, biodegradable system for the sustained
release of drugs. Science, 213, 233.
MUKHERJEE, K., BOOHAR, J., WENTLAND, D., ANSFIELD, F.J. &
HEIDELBERGER, C. (1963). Studies on fluorinated pyrimidines.
XVI. Metabolism of 5-fluorouracil-2-C14. Cancer Res., 23, 49.
POWIS, G. (1986). Anticancer drug pharmacodynamics. Cancer
Chemother. Pharmacol., 14(3), 177.
SASAKI, Y., IMAOKA, S., HASEGAWA, Y. & 7 others (1985). Changes
in distribution of hepatic blood flow induced by intra-arterial
infusion of angiotensin II in human hepatic cancer. Cancer, 55,
311.
TAYLOR, I. (1985). Colorectal liver metastases - to treat or not to
treat? Br. J. Surg., 72, 511.
WAGNER, J.G., GYVES, J.W., STETSON, P.L. & 4 others (1986).
Steady-state nonlinear pharmacokinetics of 5-Fluorouracil during
hepatic arterial and intravenous infusions in cancer patients.
Cancer Res., 46, 1499.
WEBER, G., QUEENER, S.F. & FERDINANDUS, J.A. (1971). Control
of gene expression in carbohydrate, pyrimidine and DNA
metabolism. Adv. Enzyme Regul., 9, 63.
WILLMOTT, N., CUMMINGS, J., STUART, J.F.B. & FLORENCE, A.T.
(1985). Adriamycin loaded albumin microspheres: Preparation, in-
vivo distribution and release in the rat. Biopharmacol. Drug
Dispos., 6, 91.